Evidence map›Paper›PMID 30032428›Full record

ArticleDiabetologia2018

A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.

Md Abdul Hye Khan, Lauren Kolb, Melissa Skibba, Markus Hartmann, René Blöcher, Ewgenij Proschak, John D Imig

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Soluble Epoxide Hydrolase and Diabetes Complications.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Multi-Target Approaches in Metabolic Syndrome.Frontiers in pharmacology · 2020
    Review
  19. A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE.Visnyk Kyivs'koho natsional'noho universytetu imeni Tarasa Shevchenka. Biolohiia · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Md Abdul Hye KhanDepartment of Pharmacology & Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. abhkhan@mcw.edu.ORCID http://orcid.org/0000-0001-5940-9300
Lauren KolbDepartment of Pharmacology & Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Melissa SkibbaDepartment of Pharmacology & Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Markus HartmannInstitute of Pharmaceutical Chemistry, Goethe-University of Frankfurt, Frankfurt am Main, Germany.
René BlöcherInstitute of Pharmaceutical Chemistry, Goethe-University of Frankfurt, Frankfurt am Main, Germany.
Ewgenij ProschakInstitute of Pharmaceutical Chemistry, Goethe-University of Frankfurt, Frankfurt am Main, Germany.
John D ImigDepartment of Pharmacology & Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. jdimig@mcw.edu.
Medical College of Wisconsin · USGoethe University Frankfurt · DE

Funding

Eicosanoid-based Therapy for DiabetesR01DK103616 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI IMIG, JOHN D · 2015 to 2019
$2.4M
Forschungsgemeinschaft Sachbeihilfe PR 1405/2-2, Heisenberg-Professur PRNIDDK NIH HHS R01 DK103616NIH Blueprint for Neuroscience Research DK103616
6 · The paper itself

Abstract

aims/hypothesisThe metabolic syndrome is a cluster of risk correlates that can progress to type 2 diabetes. The present study aims to evaluate a novel molecule with a dual action against the metabolic syndrome and type 2 diabetes.

methodsWe developed and tested a novel dual modulator, RB394, which acts as a soluble epoxide hydrolase (sEH) inhibitor and a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist in rat models of the metabolic syndrome-the obese spontaneously hypertensive (SHROB) rat and the obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid (ZSF1) rat. In SHROB rats we studied the ability of RB394 to prevent metabolic syndrome phenotypes, while in ZSF1 obese diabetic rats we compared RB394 with the ACE inhibitor enalapril in the treatment of type 2 diabetes and associated comorbid conditions. RB394 (10 mg/kg daily) and enalapril (10 mg/kg daily) were administered orally for 8 weeks.

resultsRB394 blunted the development of hypertension, insulin resistance, hyperlipidaemia and kidney injury in SHROB rats and reduced fasting blood glucose and HbA CONCLUSIONS/

interpretationThese findings demonstrate that a novel sHE inhibitor/PPAR-γ agonist molecule targets multiple risk factors of the metabolic syndrome and is a glucose-lowering agent with a strong ability to treat diabetic complications.

Indexed as

AnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic NephropathiesDisease Models, AnimalEnalaprilEnzyme InhibitorsEpoxide HydrolasesFatty LiverGlucose Tolerance TestHypertensionInsulin ResistanceKidney GlomerulusLiver CirrhosisMaleMetabolic SyndromeEnalaprilEnzyme InhibitorsEPHX2 protein, ratEpoxide HydrolasesPPAR gammaDiabetic nephropathyDrug developmentLiver steatosisMetabolic syndromeSoluble epoxide hydrolase

Identifiers

PMID30032428
PMCPMC6563928
OpenAlexW2884766852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.